A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

Paulina García-González; Rodrigo Morales; Lorena Hoyos; Jaxaira Maggi; Javier Campos; Bárbara Pesce; David Gárate; Milton Larrondo; Rodrigo González; Lilian Soto; Verónica Ramos; Pía Tobar; María Carmen Molina; Karina Pino-Lagos; Diego Catalán; Juan Carlos Aguillón

doi:10.1186/1479-5876-11-128

A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

Paulina García-González, Rodrigo Morales, Lorena Hoyos, Jaxaira Maggi, Javier Campos, Bárbara Pesce, David Gárate, Milton Larrondo, Rodrigo González, Lilian Soto, Verónica Ramos, Pía Tobar, María Carmen Molina, Karina Pino-Lagos, Diego Catalán^*, Juan Carlos Aguillón

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Background: Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, but also working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation, which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability and migratory capacity.Methods: TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and migration capacity.Results: After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more, in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.Conclusion: We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for autoimmunity and prevention of graft rejection.

Original language	English
Article number	128
Journal	Journal of Translational Medicine
Volume	11
Issue number	1
DOIs	https://doi.org/10.1186/1479-5876-11-128
State	Published - 24 May 2013
Externally published	Yes

Bibliographical note

Funding Information:
The authors thank to Dr. Catharien Hilkens for helping us in the standardization of the in vitro migration assay, Mr. Alvaro Rojas for flow cytometry acquisition and Mrs. Juana Orellana, Mrs. Nancy Fabres and Mrs. Ruth Mora for technical assistance. Supported by Fondecyt-Chile 110–0102, Millennium Institute on Immunology and Immunotherapy-P09-016-F and Fundación Ciencia Translacional from Chile.

Keywords

CCR7
CXCR4
Cell-based therapy
Chemokine receptors
Monocyte-derived dendritic cells
Tolerance

Access to Document

10.1186/1479-5876-11-128

Cite this

García-González, P., Morales, R., Hoyos, L., Maggi, J., Campos, J., Pesce, B., Gárate, D., Larrondo, M., González, R., Soto, L., Ramos, V., Tobar, P., Molina, M. C., Pino-Lagos, K., Catalán, D., & Aguillón, J. C. (2013). A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. Journal of Translational Medicine, 11(1), Article 128. https://doi.org/10.1186/1479-5876-11-128

@article{2c02f33dcbe846809bf5f376b602ee07,

title = "A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines",

abstract = "Background: Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, but also working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation, which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability and migratory capacity.Methods: TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and migration capacity.Results: After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more, in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.Conclusion: We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for autoimmunity and prevention of graft rejection.",

keywords = "CCR7, CXCR4, Cell-based therapy, Chemokine receptors, Monocyte-derived dendritic cells, Tolerance",

author = "Paulina Garc{\'i}a-Gonz{\'a}lez and Rodrigo Morales and Lorena Hoyos and Jaxaira Maggi and Javier Campos and B{\'a}rbara Pesce and David G{\'a}rate and Milton Larrondo and Rodrigo Gonz{\'a}lez and Lilian Soto and Ver{\'o}nica Ramos and P{\'i}a Tobar and Molina, {Mar{\'i}a Carmen} and Karina Pino-Lagos and Diego Catal{\'a}n and Aguill{\'o}n, {Juan Carlos}",

note = "Funding Information: The authors thank to Dr. Catharien Hilkens for helping us in the standardization of the in vitro migration assay, Mr. Alvaro Rojas for flow cytometry acquisition and Mrs. Juana Orellana, Mrs. Nancy Fabres and Mrs. Ruth Mora for technical assistance. Supported by Fondecyt-Chile 110–0102, Millennium Institute on Immunology and Immunotherapy-P09-016-F and Fundaci{\'o}n Ciencia Translacional from Chile.",

year = "2013",

month = may,

day = "24",

doi = "10.1186/1479-5876-11-128",

language = "English",

volume = "11",

journal = "Journal of Translational Medicine",

issn = "1479-5876",

publisher = "BioMed Central Ltd.",

number = "1",

}

García-González, P, Morales, R, Hoyos, L, Maggi, J, Campos, J, Pesce, B, Gárate, D, Larrondo, M, González, R, Soto, L, Ramos, V, Tobar, P, Molina, MC, Pino-Lagos, K, Catalán, D & Aguillón, JC 2013, 'A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines', Journal of Translational Medicine, vol. 11, no. 1, 128. https://doi.org/10.1186/1479-5876-11-128

A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. / García-González, Paulina; Morales, Rodrigo; Hoyos, Lorena et al.
In: Journal of Translational Medicine, Vol. 11, No. 1, 128, 24.05.2013.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

AU - García-González, Paulina

AU - Morales, Rodrigo

AU - Hoyos, Lorena

AU - Maggi, Jaxaira

AU - Campos, Javier

AU - Pesce, Bárbara

AU - Gárate, David

AU - Larrondo, Milton

AU - González, Rodrigo

AU - Soto, Lilian

AU - Ramos, Verónica

AU - Tobar, Pía

AU - Molina, María Carmen

AU - Pino-Lagos, Karina

AU - Catalán, Diego

AU - Aguillón, Juan Carlos

N1 - Funding Information: The authors thank to Dr. Catharien Hilkens for helping us in the standardization of the in vitro migration assay, Mr. Alvaro Rojas for flow cytometry acquisition and Mrs. Juana Orellana, Mrs. Nancy Fabres and Mrs. Ruth Mora for technical assistance. Supported by Fondecyt-Chile 110–0102, Millennium Institute on Immunology and Immunotherapy-P09-016-F and Fundación Ciencia Translacional from Chile.

PY - 2013/5/24

Y1 - 2013/5/24

N2 - Background: Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, but also working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation, which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability and migratory capacity.Methods: TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and migration capacity.Results: After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more, in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.Conclusion: We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for autoimmunity and prevention of graft rejection.

AB - Background: Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, but also working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation, which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability and migratory capacity.Methods: TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and migration capacity.Results: After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more, in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.Conclusion: We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for autoimmunity and prevention of graft rejection.

KW - CCR7

KW - CXCR4

KW - Cell-based therapy

KW - Chemokine receptors

KW - Monocyte-derived dendritic cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84878005244&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-11-128

DO - 10.1186/1479-5876-11-128

M3 - Article

C2 - 23706017

AN - SCOPUS:84878005244

SN - 1479-5876

VL - 11

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

IS - 1

M1 - 128

ER -

A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this